4th Annual Biomarker and Companion Diagnostics Conference

To ensure maximum safety, MarketsandMarkets has initiated a mandatory COVID-19 vaccination policy for all in-person attendees across all our physical events. Attendees will be asked to provide proof of vaccination. Additional details on the vaccine policy will be provided upon registration.

Attendees that cannot participate due to this policy, or because of any travel restrictions, are encouraged to participate in the event by registering virtually and attending the event which will be live streamed on our very well appreciated virtual event platform!

These policies may shift as the virus subsides, but we firmly feel this is the right time for MarketsandMarkets to reopen our much awaited physical events safely! We stay committed in our fight against COVID, a variety of new protocols and elevated practices are in place at the venue along with maintaining high standards of cleanliness. We are strictly adhering to the safety guidelines outlined by the Government. We also encourage our participants to review all federal, state, and local permitted traveler guidance before travel and making a reservation.

Biomarker is constantly evolving as the latent for the development of innovative drugs and diagnostic assays for early detection of disease. The major developments are witnessed in immune therapies where breakthroughs will be appearing soon.

The 4th Annual Biomarker and Companion Diagnostics Conference scheduled to be held on 7th-8th February 2019 in San Diego, CA would address the gaps between early stage biomarker development and the commercialization stage of biomarkers. Regarding commercialization of biomarkers, leading industry and academic experts would share their case studies focusing on advancements in the companion diagnostics area. The keynote presentations would also help the attendees understand the issues related to clinical translation of biomarkers.

Learn from 20+ industry leading speakers who will be sharing their presentations and use cases on Non-invasive diagnosis of lung cancer, disruptive technologies in biomarker research, Next-generation CAR T-cells, Cloud software solutions for Clinical assays experiences.

Facilitated networking sessions to ensure quality interactions which include one on one query handling by biomarker experts and the opportunity to develop long-lasting business relationships and networking opportunities with senior peers.

Latest updates on regulatory guidelines and approvals, NGS and novel technologies in biomarker discovery, Commercialization of biomarkers in therapeutic and CDx applications with senior leaders from the Biomarker Industry.

We also have a UK Edition which will be held on 3 - 4 October 2019. View more details about the conference here.

We will soon be announcing the Dates and Venue for the 5th Biomarker and Companion Diagnostics Conference 2020. Email us on [email protected] to book your place at the conference.